| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 2 data readout example | SER-155 Prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant | Phase 2 | — | Subscribe to access the data. | Microbiome-Based Therapies | Infectious Diseases | |
phase 2 data readout example | SER-155 Prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant | Phase 2 | — | Subscribe to access the data. | Microbiome-Based Therapies | Infectious Diseases | |
phase 2 data readout example | SER-155 Prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant | Phase 2 | — | Subscribe to access the data. | Microbiome-Based Therapies | Infectious Diseases |
Recent Updates
Recently added Catalysts
Seres Therapeutics, Inc.$6.11
-0.63 (-9.35%)
D 28Pipeline Score Richly Valued Biotech · Commercial
Market Cap
76.70 M
EPS
-5.02
P/E Ratio
-
Value Trade
367.23 K
SEC Financials
Q1 2026Dilution Risk
Revenue
358.00 K
R&D Expenses
13.20 M
Operating CF
-16.36 M
Total Assets
117.62 M
Total Liabilities
91.12 M
Equity
26.50 M
D/E Ratio
12,345
1.28 %
Week
-9.07 %
1 Month
-6.49 %
3 Month
-60.99 %
6 Month
-98.18 %
5 Year
-98.61 %
All Time
Cash Data
Cash Position
29.83 M
Monthly Burn
5.45 M
Runway
3.5 mo
Burn Trend
SEC Filing
May 5, 2026
Overview
Volume
154.45 K
52 Week Range
6.56 - 29.98
% held by Insiders
24.21 %
% held by Institutions
12.38 %
Enterprise Value
127.36 M
Total Shares
9.69 M
Short %
2.29 %
Float Shares
6.86 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Seres Therapeutics, Inc.
361Total events
11Upcoming
105Tier-1 (high impact)
2016 – 2027Coverage
Upcoming catalysts 11
Oct 1, 2026
T2Milestone Payment
Nestlé Health Science to pay $25M in two installments for VOWST milestone buyout
TBD
T1Partnership / License
Engaged potential collaborators to support clinical development of SER-603
TBD
T1Partnership / License
Engaging with multiple parties regarding potential business development and partnerships to secure capital for SER-155 and pipeline
Event history 350
Jul 8, 2026
●Oral PresentationSER-155Presentation
Webcast to discuss IST results
immune checkpoint inhibitor-related enterocolitis (irEC)source ↗
Jul 8, 2026
▲Topline ReadoutSER-155Clinical Data
Topline results from IST of SER-155 in irEC: 80% immunosuppressive-free clinical response at Day 15
immune checkpoint inhibitor-related enterocolitis (irEC)source ↗
Jul 1, 2026
▲Milestone PaymentCorporate
Nestlé Health Science to pay $25M in two installments for VOWST milestone buyout
Q3 2026
Jun 2026
◆Topline ReadoutSER-155Clinical Data
Clinical data from investigator-sponsored SER-155 study in irEC expected later this month
immune checkpoint inhibitor-related enterocolitissource ↗
Q2 2026
●Runway Guidance UpdateCorporate
Cash runway guidance: expects to fund operations through Q2 2026
May 19, 2026
◆Oral PresentationPresentation
Company overview presentation at H.C. Wainwright 4th Annual BioConnect Investor Conference
May 3, 2026
▲Poster PresentationSER-603Presentation
Poster of Distinction presentation at DDW 2026: The Rational Design of SER-603
inflammatory bowel diseasesource ↗
May 2026
◆Topline ReadoutSER-155Clinical Data
Clinical readout from investigator-sponsored SER-155 study in irEC expected in the coming weeks
immune checkpoint inhibitor-related enterocolitissource ↗
Apr 21, 2026
●Oral PresentationPresentation
Symposium presentation on targeting gut microbiome in hematopoietic cell transplantation at ESCMID Global 2026
immunocompromised patients (hematopoietic cell transplantation)source ↗
Apr 20, 2026
▲Poster PresentationSER-155Presentation
Poster presentation of SER-155 Phase 1b biomarker and clinical pharmacology data at ESCMID Global 2026
allogeneic hematopoietic cell transplantation (allo-HCT)source ↗
Drug Pipeline Intelligence
D28
Pipeline Score $9M
Pipeline ValueRichly Valued
Valuation Signal5
Drugs Scored0.1x
rNPV / MCap Top 30%
Micro Cap (rank 639 of 911)
Percentile RankSeres Therapeutics, Inc. faces pipeline headwinds (28/100), with $386M risk-adjusted pipeline value, led by SER-109 in Clostridium Difficile Infection (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SER-109 Monoclonal antibody | Clostridioides Difficile Infection | Phase 3 | NCT03183141 | 57% | $155M | COMPLETED | 263 | - | - | Apr 29, 2022 | - | Apr 10, 2023 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SER-155 BreakthroughFast Track | immune checkpoint inhibitor-related enterocolitis (irEC) | — | 2026-07-08 | clinical response: 80%; participants: 15; responders: 12; complete remission: 33%; grade improvement: 67% Read More | Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment Read More | |
SER-155 BreakthroughFast Track | immune checkpoint inhibitor-related enterocolitis (irEC) | — | 2026-07-08 | clinical response: 80%; participants: 15; responders: 12; complete remission: 33%; grade improvement: 67% Read More | Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment Read More | |
SER-155 BreakthroughFast Track | immune checkpoint inhibitor-related enterocolitis (irEC) | — | 2026-07-08 | clinical response: 80%; participants: 15; responders: 12; complete remission: 33%; grade improvement: 67% Read More | Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in MCRB
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
MCRB Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
MCRB▼ -12.3%on this news
Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment
Seres Therapeutics announced promising early clinical data for SER-155, showing that 80% of patients with immune checkpoint inhibitor-related enterocolitis (irEC) achieved a clinical response without the need for immunosuppressive drugs. The study, conducted at Memorial Sloan Kettering Cancer Center, demonstrated that SER-155 was well tolerated and could potentially allow patients to continue their cancer treatments without interruption. The results support further development of SER-155 for irEC and other inflammatory diseases.
Read more →MCRBSeres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis
Seres Therapeutics announced a webcast on July 8, 2026, to discuss top-line results from an investigator-sponsored trial of SER-155 for immune checkpoint inhibitor-related enterocolitis. Conducted at Memorial Sloan Kettering Cancer Center, the trial aims to evaluate the efficacy and safety of SER-155 in patients suffering from this serious side effect of cancer therapy. The results may inform future treatment options that do not require immunosuppressive therapy.
Read more →MCRBSERES THERAPEUTICS ANNOUNCES TWO TRANSACTIONS TO STRENGTHEN BALANCE SHEET, REDUCE OPERATING COSTS AND EXTEND PROJECTED OPERATING CASH RUNWAY WELL INTO THE FIRST QUARTER OF 2027 Agreement with Nestl Health Science provide
Seres Therapeutics announced two significant transactions aimed at enhancing its financial stability. The company has entered into an agreement with Nestl Health Science that provides $25 million in future payments and has restructured its lease to lower annual facility costs. These actions are expected to extend Seres' operating cash runway into the first quarter of 2027, allowing continued focus on advancing its therapeutic pipeline. Upcoming clinical data from the SER-155 study in enterocolitis is anticipated later this month.
Read more →MCRBSeres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference
Seres Therapeutics, Inc. will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The presentation will provide an overview of the company's developments, including its focus on live biotherapeutics for inflammatory diseases. A live webcast will be available for those unable to attend.
Read more →MCRBSERES THERAPEUTICS REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Clinical readout from investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis expected in th
Seres Therapeutics has reported its first quarter 2026 financial results, highlighting progress across its live biotherapeutic programs. The company anticipates an important clinical readout for SER-155 in treating immune checkpoint inhibitor-related enterocolitis within weeks. Despite facing financial losses and addressing capital requirements, Seres remains focused on advancing its portfolio and securing funding to support ongoing development efforts. As of March 31, 2026, it reported $29.8 million in cash, sufficient to operate through Q3 2026.
Read more →MCRBSeres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Seres Therapeutics presented promising preclinical data for SER-603, a next-generation biotherapeutic candidate for inflammatory bowel disease (IBD), at Digestive Disease Week 2026. The data highlight SER-603's design targeting microbial functions linked to mucosal healing and inflammation. The presentation received 'Poster of Distinction' recognition, showcasing the potential for improved patient outcomes through a biomarker-driven approach.
Read more →MCRBSeres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Seres Therapeutics presented promising data on SER-155 at the ESCMID 2026 congress. The Phase 1b study demonstrated a significant shift in gastrointestinal microbiome composition and improved epithelial barrier integrity in patients undergoing allogeneic hematopoietic cell transplantation. The findings suggest SER-155 could reduce bloodstream infection risks in this vulnerable population.
Read more →MCRBSeres Therapeutics to Present at CARB-X Investor Day
Seres Therapeutics will present at the 2026 CARB-X Investor Day on April 16, 2026, focusing on its collaboration with CARB-X to combat antimicrobial resistance. The company is advancing SER-428, a liquid formulation aimed at patients unable to take oral capsules. The event will showcase innovative therapeutics and foster partnerships in the fight against drug-resistant bacteria.
Read more →MCRBSeres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Seres Therapeutics reported its fourth quarter and full year 2025 financial results, highlighting progress in its live biotherapeutics programs. The company is set to release clinical data for SER-155 in Q2 2026, targeting immune checkpoint-related enterocolitis. Despite a net income improvement, Seres is actively seeking funding to support its ongoing and future projects.
Read more →MCRBSeres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates
Seres Therapeutics has appointed Richard N. Kender as Executive Chair and Interim CEO, aiming to advance its live biotherapeutic programs. The company focuses on inflammatory and immune diseases, with a key study on SER-155 expected to report results in Q2 2026. The firm is actively seeking funding to support its initiatives.
Read more →MCRB▼ -41.7%on this news
Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases
Seres Therapeutics has made significant progress with the SER-155 Phase 2 study protocol, which is now finalized with the FDA. However, the company will pause further investments in this program while focusing on earlier-stage pipeline developments in inflammatory and immune diseases. A workforce reduction is also being implemented to extend the company's cash runway through Q3 2026.
Read more →MCRBSeres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
Seres Therapeutics has published two significant manuscripts in high-impact journals that demonstrate the clinical efficacy and biological mechanisms of its product VOWST, which is aimed at preventing recurrent Clostridioides difficile infection. The publications provide further validation of Seres' live biotherapeutic strategy and detail the performance of VOWST in various patient populations. Additionally, the company's pipeline, including the lead candidate SER-155, is showing potential in addressing serious infections in at-risk patients, enhanced by findings using the Seres MbTx platform. The findings are expected to bolster the development of Seres' next-generation treatments.
Read more →MCRBSeres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics, Inc. will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. The event will be accessible via a live webcast, allowing investors and the public to engage with the company's management. Seres continues to advance its innovative biotherapeutics, particularly SER-155, aimed at improving outcomes for vulnerable patient populations.
Read more →MCRB▼ -7.6%on this news
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Seres Therapeutics has reported its Q3 2025 financial results and updates on its SER-155 Phase 2 study aimed at preventing bloodstream infections in patients undergoing stem cell transplants. Following positive FDA feedback, the company is finalizing the study protocol and expects interim results within a year, contingent on securing funding. Additionally, cost-reduction measures have been implemented to extend operational capacity through mid-2026.
Read more →MCRB▼ -6.6%on this news· ran to -19% by day 3
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
Seres Therapeutics has announced a conference call on November 5, 2025, to discuss its third quarter 2025 financial results and provide updates on business developments. The call is accessible via phone or live audio webcast, and a replay will be available for 21 days afterward. The company is noted for its focus on improving outcomes in vulnerable patient populations, particularly with its product SER-155, which has received Breakthrough Therapy designation.
Read more →MCRBSeres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
Seres Therapeutics has been awarded up to $3.6 million from CARB-X to develop a liquid formulation of SER-155, aimed at patients vulnerable to bloodstream infections. The funding will enhance accessibility for patients unable to take oral capsules, particularly those in intensive care. SER-155 has demonstrated significant efficacy in reducing bacterial infections in clinical trials.
Read more →MCRBSeres Therapeutics to Present New Post Hoc Data From SER-155 Phase 1b Trial at IDWeek 2025, Highlighting Potential to Improve Outcomes in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant
Seres Therapeutics announced that new post hoc data from its SER-155 Phase 1b trial will be presented at IDWeek 2025. The data highlights SER-155's effectiveness in reducing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant. The company is also finalizing plans for a Phase 2 study following positive FDA feedback.
Read more →MCRB▲ +6.3%on this news· ran to +17% by day 1
Seres Therapeutics Announces Further Constructive Feedback from FDA on SER-155 Phase 2 Study Protocol and Implements Cost Reduction Actions to Extend Cash Runway
Seres Therapeutics has received constructive feedback from the FDA regarding the Phase 2 study protocol for SER-155, aimed at preventing bloodstream infections in patients undergoing stem cell transplants. The company plans to finalize the protocol and expects interim results within 12 months. To extend its cash runway, Seres is reducing operating costs and workforce by 25%.
Read more →MCRBSeres Therapeutics to Participate in H.C. Wainwright 27th Annual Global Investment Conference
Seres Therapeutics, Inc. (Nasdaq: MCRB) will present at the H.C. Wainwright Global Investment Conference on September 8, 2025. The company focuses on live biotherapeutics and has successfully developed VOWST™, the first FDA-approved orally administered microbiome therapeutic. SER-155, another key product, aims to reduce bloodstream infections in patients undergoing allo-HSCT.
Read more →MCRBSERES THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Following FDA input, Seres submitted Phase 2 study protocol to FDA for SER-155 for the prevention of bloodstream infections (
Seres Therapeutics reported its second quarter 2025 financial results and updates on its business operations. The company has submitted a Phase 2 study protocol for SER-155, aimed at preventing bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplants. Encouraged by feedback from the FDA, Seres is actively seeking partnerships and capital to support further development. Additionally, the company has received a $25 million payment from Nestlé Health Science to aid in its ongoing research and operations.
Read more →MCRB▼ -10.5%on this news
Seres Therapeutics Announces Leadership Transition
Seres Therapeutics has appointed Thomas DesRosier and Marella Thorell as co-CEOs following Eric Shaff's departure. The company is actively seeking partnerships to secure capital for advancing SER-155, which shows promise in reducing bloodstream infections. This leadership change comes after significant achievements, including the FDA approval of the first oral microbiome therapy.
Read more →MCRB▼ -10.5%on this newsshared move
Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025
Seres Therapeutics, Inc. (Nasdaq: MCRB) announced a conference call and live audio webcast scheduled for August 6, 2025, to discuss its second quarter financial results and provide updates on its business. The company, which focuses on live biotherapeutics, is known for successfully developing VOWST™, the first FDA-approved microbiome therapeutic. Additionally, its candidate SER-155, which targets bloodstream infections, has received Breakthrough Therapy designation and shows promise in clinical trials.
Read more →MCRB▼ -5.7%on this news
Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting
Seres Therapeutics announced the presentation of new exploratory biomarker data from its SER-155 Phase 1b study at the 2025 ASCO Annual Meeting. The data indicate improved intestinal barrier integrity and a significant reduction in bloodstream infections. The findings suggest SER-155 may enhance immune recovery in patients undergoing allo-HSCT, supporting further clinical development. The company plans to submit a Phase 2 trial protocol to the FDA soon.
Read more →MCRBSERES THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES In line with recent FDA feedback, Seres expects to submit a Phase 2 study protocol to FDA in the coming weeks for SER-155 for
Seres Therapeutics reported its first quarter 2025 financial results alongside significant business updates. The company announced plans to submit a Phase 2 study protocol for SER-155, aiming to prevent bloodstream infections in adults undergoing certain transplants. Positive results from a Phase 1b study highlighted a 77% reduction in these infections, and the company is engaged in partnership discussions to advance SER-155's clinical development. Notably, SER-155 has already received Breakthrough Therapy designation from the FDA, emphasizing its potential impact in addressing unmet medical needs.
Read more →MCRBSeres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
Seres Therapeutics will showcase new findings at the 2025 Digestive Disease Week Conference, focusing on the potential of live biotherapeutics for treating inflammatory and immune diseases. The presentations will include exploration of biomarkers linked to microbiome disruptions in conditions like ulcerative colitis and Crohn’s disease. The company seeks partnerships to further the development of its innovative biotherapeutics, including SER-155, which has shown promise in reducing complications in vulnerable patient populations. This highlights Seres' commitment to advancing therapies in the evolving field of microbiome research.
Read more →MCRB▲ +19.2%on this news
Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
Seres Therapeutics, Inc. (Nasdaq: MCRB) is set to announce its first quarter 2025 financial results and business updates during a conference call on May 7, 2025. The event will be accessible via phone and live webcast. The company has been recognized for its innovative approach with SER-155, designed to reduce bloodstream infections in vulnerable patient populations, and continues to focus on various therapeutic developments following the approval of their first product, VOWST.
Read more →MCRB▼ -7.9%on this news
SERES THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Recent FDA feedback received on SER-155 allogeneic hematopoietic stem cell transplant (allo-HSCT) next study pr
Seres Therapeutics recently released its fourth quarter and full year 2024 financial results. The company has received positive feedback from the FDA regarding its SER-155 allogeneic hematopoietic stem cell transplant program, which demonstrated a significant reduction in bloodstream infections. Seres plans to submit a draft study protocol to the FDA in Q2 2025 and is advancing discussions for strategic partnerships. The company expects to fund operations through the first quarter of 2026, bolstered by anticipated payments from Nestlé.
Read more →MCRB▼ -10.5%on this news
Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025
Seres Therapeutics, Inc. has announced a conference call on March 13, 2025, to discuss their fourth quarter and full year 2024 financial results, along with business updates. The call will be accessible via phone and a live webcast on their website. Seres is recognized for its novel live biotherapeutics, including the FDA-approved product VOWST and the promising candidate SER-155, which has received Breakthrough Therapy designation. The company aims to advance treatments for various medically vulnerable populations.
Read more →MCRBSeres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
Seres Therapeutics has received positive feedback from the FDA regarding the development of its lead biotherapeutic, SER-155, for patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). The FDA recommends a Phase 2 study with a primary endpoint focused on reducing bloodstream infections within 30 days post-transplant. The company aims to submit a protocol based on this feedback in Q2 2025. Seres continues to seek partners for further development and has previously shown a significant reduction in bloodstream infections in earlier trials.
Read more →MCRB▼ -5.8%on this news· ran to +17% by day 3
J.P. Morgan Conference Seres Therapeutics Investor Presentation
At the J.P. Morgan Conference, Seres Therapeutics outlined its financial performance and clinical development plans, with a focus on the SER-155 candidate. The recent VOWST asset sale is highlighted as a transformative move, providing necessary funds to extend operational runway and support pipeline advancement. Despite promising clinical trial data and a well-tolerated safety profile for SER-155, Seres continues to grapple with significant financial losses and a dependency on external partners for development processes. The company is actively pursuing partnerships to accelerate its research and expand its market opportunities.
Read more →MCRB▼ -5.8%on this news· ran to +17% by day 3
Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
Seres Therapeutics, Inc. announced it received a $50 million installment payment from the sale of its VOWST business to Nestlé Health Science. This payment was anticipated as the company fulfills its transition obligations, providing a cash infusion that extends its operational runway into early 2026. Despite the positive cash flow, Seres faces challenges, such as potential future losses and reliance on third-party ventures, which may impact its financial outlook. The company continues to advance its pipeline with promising candidates like SER-155.
Read more →MCRBSeres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates New SER-155 Phase 1b study biomarker data in allogeneic hematopoietic stem cell transpl
Seres Therapeutics announced promising results from its Phase 1b clinical study of SER-155, focused on patients undergoing allogeneic stem cell transplantation. The study showed significant improvement in biomarkers for epithelial barrier integrity and a reduction in systemic inflammation. These findings are supported by already established clinical results showing reduced rates of bloodstream infections. The company plans to engage with the FDA regarding further development of SER-155, which has received both Breakthrough Therapy and Fast Track designations.
Read more →MCRBSeres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
Seres Therapeutics, Inc. announced its participation in the 2025 J.P. Morgan Healthcare Conference, where CEO Eric Shaff will present on January 16. The company will highlight the advancements in its biotherapeutics pipeline, particularly SER-155, which recently received Breakthrough Therapy designation from the FDA for reducing bloodstream infections in specific patient populations. The designation is backed by promising clinical trial results, indicating SER-155's efficacy in reducing infection rates in patients undergoing allogeneic hematopoietic stem cell transplants, as well as other medically vulnerable groups. Seres is seeking financial partnerships to further explore SER-155's development and expand its pipeline of candidates.
Read more →MCRB▼ -11.1%on this news
SERES THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES SER-155 Phase 1b placebo-controlled clinical results demonstrated significant reduction in both bacterial bloodstream infectio
Seres Therapeutics has reported third quarter 2024 financial results, highlighting positive clinical outcomes for SER-155, which significantly reduced bacterial bloodstream infection rates in patients undergoing allo-HSCT. The company has strengthened its financial position following the VOWST sale and expects to fund operations into Q4 2025. Aiming to expand SER-155's use, Seres plans to seek a strategic partnership while preparing for future clinical studies and has requested FDA designations to expedite the process. The company is transitioning toward focusing on multiple patient populations with additional live biotherapeutic candidates in the pipeline.
Read more →MCRB▼ -7%on this news
Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
Seres Therapeutics, Inc. will host a conference call on November 13, 2024, to discuss its third quarter financial results and provide business updates. The call will be accessible via phone and webcast, showing the company's commitment to transparency. Seres Therapeutics specializes in live biotherapeutics and recently achieved a significant milestone with their FDA-approved product VOWST™. They are also advancing other promising therapies aimed at improving health outcomes in vulnerable patient populations.
Read more →MCRBSeres Therapeutics Announces Completion of VOWST Asset Sale to Soci t des Produits Nestl S.A Transaction supports further development of SER-155, following recent promising clinical data, and other cultivated live biothe
Seres Therapeutics has successfully completed the sale of its VOWST business to Nestlé Health Science, bolstering its financial stability and enabling the progression of its SER-155 treatment. Recent clinical data showed SER-155's effectiveness in reducing bloodstream infections among patients undergoing allo-HSCT. With the sale proceeds, Seres aims to extend its cash runway into the fourth quarter of 2025, while also planning for potential Breakthrough Therapy designation for SER-155. However, this transaction will result in a significant workforce reduction as some team members transition to Nestlé.
Read more →MCRBSeres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
Seres Therapeutics, Inc. will participate in the Cantor Global Healthcare Conference on September 18, 2024, where CEO Eric Shaff will present. This event highlights the company's ongoing commitment to enhancing patient outcomes through innovative live biotherapeutics. Seres is recognized for its development of VOWST™, the first FDA-approved orally administered microbiome therapeutic, and is advancing its project SER-155 along with other therapeutic candidates.
Read more →MCRB▼ -8.6%on this newsshared move
Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
Seres Therapeutics has announced positive results from Cohort 2 of its Phase 1b study of SER-155, aimed at patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT). The study demonstrated a significant reduction in bacterial bloodstream infections and a lower incidence of febrile neutropenia compared to placebo. SER-155 was well tolerated, with no reported serious adverse events. Given these results, the company plans to seek Breakthrough Therapy designation from the FDA to expedite the drug's development.
Read more →MCRB▼ -8.6%on this newsshared move
SER-155 Phase 1b Readout
Seres Therapeutics, Inc. reported on the Phase 1b readout for SER-155, an investigational live oral biotherapeutic aimed at reducing complications for allo-HSCT recipients. The study demonstrated that SER-155 was generally well tolerated with no serious treatment-related adverse events. Data indicated that the compound may prevent infections associated with this treatment regimen. Furthermore, the study has obtained FDA Fast Track Designation, which supports its developmental pathway, although challenges regarding profitability and funding remain.
Read more →MCRBINDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (PCAOB ID 238) F-2 Consolidated Balance Sheets as of
Seres Therapeutics has released its consolidated financial statements for the years ended December 31, 2023, and 2022. The audit report indicates that the company has faced significant financial challenges, including ongoing losses and negative cash flows. There is a critical concern regarding its ability to continue operations without securing additional funding. Furthermore, the financial statements highlight complexities in recognizing collaboration profit-loss sharing from a license agreement with Nestlé.
Read more →MCRB▼ -7%on this newsshared move
SERES THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES SER-155 Phase 1b placebo-controlled Cohort 2 clinical readout on track for September VOWST asset sale to provide $175M cash i
Seres Therapeutics reported its second quarter 2024 financial results, highlighting a forthcoming clinical readout for SER-155 and a significant upcoming cash infusion from the VOWST asset sale. The transaction, pending stockholder approval, aims to strengthen the company's balance sheet and facilitate the development of its biotherapeutic pipeline. The asset sale is projected to eliminate senior secured debt and allow Seres to fund operations through Q4 2025. Overall, the company shows a positive outlook as it streamlines operations and focuses on improving patient outcomes in vulnerable populations.
Read more →MCRB▼ -21.1%on this news· ran to -31% by day 1
SERES THERAPEUTICS ANNOUNCES SIGNING OF VOWST ASSET PURCHASE AGREEMENT WITH NESTL HEALTH SCIENCE Upon closing, Seres to receive $175M cash infusion, including an upfront payment, prepayment of a future commercial milesto
Seres Therapeutics has signed an asset purchase agreement with Nestlé Health Science to sell its VOWST business, which will provide a $175 million cash infusion. This funding will help Seres retire its existing debt and support its ongoing clinical programs, particularly the SER-155 pipeline. The agreement includes future payments based on VOWST sales milestones and mandates a significant workforce reduction as operations are streamlined. The completion of the deal is subject to shareholder approval, and additional installment payments are planned for 2025.
Read more →MCRB▼ -21.1%on this news· ran to -31% by day 1
Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024
Seres Therapeutics, Inc. (MCRB) has announced a conference call and live audio webcast scheduled for August 13, 2024, to discuss its second quarter financial results and provide business updates. The company is focused on using oral cultivated live biotherapeutics to improve patient outcomes, particularly in vulnerable populations. Notably, Seres recently led the successful development of VOWST™, the first FDA-approved orally administered microbiome therapeutic. The firm is currently evaluating SER-155 in a Phase 1b study aimed at preventing gastrointestinal infections in stem cell transplant patients.
Read more →MCRBForm of Support Agreement This SUPPORT AGREEMENT (this " Agreement ") is made as of
Seres Therapeutics, Inc. has entered into a Support Agreement related to an Asset Purchase Agreement with Nestlé S.A. This Agreement involves the stockholder's commitment to vote in favor of the asset sale and associated transactions. The stockholder is also restricted from engaging in actions that could undermine this agreement, reinforcing a strong position toward shareholder approval of the transaction.
Read more →MCRB▼ -28%on this news
Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Seres Therapeutics has announced the grant of inducement equity awards covering 6,188 shares to a new employee, including stock options and restricted stock units. This decision was made by the company's Compensation and Talent Committee under its 2022 Employment Inducement Award Plan, aligning with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price set at $1.14 per share and include specific vesting schedules aimed at promoting employee retention.
Read more →MCRB▼ -32.5%on this news
SERES THERAPEUTICS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES Continued market adoption of VOWST with approximately 1,411 patient enrollment forms received, approximately 1,083 new patient
Seres Therapeutics, Inc. reported its first quarter 2024 results, highlighting continued market adoption of its product VOWST, which has garnered about 1,083 new patient starts and generated $10.1 million in net sales. The company also completed enrollment for its SER-155 Phase 1b study and anticipates sharing results by the end of Q3 2024. Despite a decline in cash reserves since 2023, Seres remains optimistic about its pipeline and growth opportunities. However, they are also considering various measures to secure additional funding and manage cash flow.
Read more →MCRB▼ -7%on this news
Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates VOWST net sales of $10.4 million for the fourth quarter of 2023 and $19.6 million since launch in June through
Seres Therapeutics (MCRB) released its financial results for Q4 and the full year of 2023, highlighting notable sales for its microbiome therapeutic VOWST. The product achieved significant adoption with over 2,800 patient enrollment forms submitted since launch. Despite a substantial net loss of $113.7 million for the year, Seres has implemented a corporate restructuring expected to save annual costs significantly. Looking ahead, the company anticipates clinical data from its SER-155 study in Q3 2024, with the potential to address severe infections in immunocompromised patients.
Read more →MCRB▼ -15.4%on this news
Seres Therapeutics Announces VOWST Commercial Launch Update and US FDA Fast Track Designation for SER-155 VOWST preliminary net sales of approximately $10.4 million (unaudited) for the fourth quarter of 2023 Significant
Seres Therapeutics announced noteworthy updates regarding its microbiome therapeutic VOWST, which has achieved preliminary net sales of about $10.4 million for Q4 2023 since its launch in June 2023. The drug aims to prevent recurrent Clostridioides difficile infections and has shown significant adoption among patients and healthcare providers. Additionally, SER-155 has received US FDA Fast Track Designation, potentially accelerating its clinical development. The company is optimistic about continuing its commercial success into 2024, particularly with ongoing education efforts for healthcare providers.
Read more →MCRB▼ -8.3%on this newsshared move
Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to the anticipated supply and degree of market ac
Seres Therapeutics has highlighted the successful launch of its FDA-approved microbiome therapy, VOWST, which aims to prevent recurrent C. difficile infections. The company reported over 2,000 patient starts since the therapy's introduction in June 2023. Additionally, SER-155 has been granted Fast Track designation by the FDA, and phase 1b clinical data is expected in Q3 2024. The presentation underscores the urgency of addressing recurrent CDI, a significant medical issue with thousands of deaths annually in the U.S.
Read more →MCRB▼ -35.3%on this news
Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST Net Sales of $7.6 Million Rapid growth of VOWST continues with more than 1,500 patient enrollment forms received since FDA approval Announce
Seres Therapeutics has reported solid third-quarter results for 2023, showcasing VOWST's net sales of $7.6 million and more than 1,500 patient enrollments following its FDA approval. To support ongoing growth and ensure long-term sustainability, Seres announced a strategic restructuring involving a 41% workforce reduction, expected to yield annual cash savings of $75-$85 million. Despite facing a reported net loss of $47.9 million for the quarter, Seres aims to prioritize VOWST commercialization while advancing the SER-155 Phase 1b study.
Read more →MCRB▼ -6.9%on this news
Seres Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates VOWST TM is the first orally administered microbiome therapeutic FDA-approved for prevention of recurrence of C. difficile in
Seres Therapeutics reported its second quarter financial results and business updates, highlighting the FDA approval of VOWST, the first orally administered microbiome therapeutic for preventing recurrent C. difficile infections in adults. Early commercial launches have shown promising uptake among healthcare providers and patients. The company also announced initial favorable data from its SER-155 clinical trials, expected to have further results in mid-2024. Overall, Seres has demonstrated a positive trajectory in its business milestones and clinical research endeavors.
Read more →MCRB▼ -7.1%on this news
Seres Therapeutics June 2023 Corporate Overview Forward Looking Statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, i
Seres Therapeutics provided a corporate overview highlighting forward-looking statements related to its microbiome therapeutic VOWST. The FDA-approved VOWST aims to prevent recurrent Clostridioides difficile infections (rCDI) in adults and has shown promising initial reception among healthcare professionals. However, risks include uncertainty regarding market acceptance and the product's limitations in treating CDI directly. The company continues its strategic focus on microbiome therapies, including ongoing development for other related health conditions.
Read more →MCRBSeres Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates VOWST TM microbiota-based therapeutic approved for prevention of recurrence of C. difficile infection in adults following anti
Seres Therapeutics recently announced its first quarter 2023 financial results and highlighted the FDA approval of VOWST, a microbiota-based therapeutic for preventing the recurrence of C. difficile infection in adults. VOWST is expected to launch in June, benefiting patients with recurrent CDI. Additionally, Seres provided updates on its investigational SER-155, which shows promising early results for preventing infections and other complications in patients undergoing stem cell transplants. The company also reported a net loss for the quarter, indicating ongoing financial challenges amidst these advancements.
Read more →MCRBSeres Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates SER-109 Biologics License Application (BLA) under review with U.S. Food and Drug Administration (FDA) with targ
Seres Therapeutics has reported its fourth quarter and full year 2022 financial results alongside updates on its key therapeutic candidates, SER-109 and SER-155. The Biologics License Application for SER-109 is currently under FDA review, with a planned commercial launch following potential approval. Positive results from the Phase 3 studies indicate SER-109's efficacy in treating recurrent C. difficile infection, while SER-155 continues in a Phase 1b trial. The company faces financial losses yet remains optimistic about future developments and market opportunities in microbiome therapeutics.
Read more →MCRBSome of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to the potential approval and launch of SER-109;
The presentation at the 41st Annual J.P. Morgan Healthcare Conference discussed Seres Therapeutics' progress with its microbiome therapeutic SER-109, which is under FDA review. The company aims to launch SER-109 for recurrent C. difficile infections, boasting a positive clinical response rate. Forward-looking statements were made regarding the anticipated approval and potential launch, alongside identified risks that could affect outcomes. The collaboration with Nestl Health Science is expected to bolster product reach pending FDA approval.
Read more →MCRB▼ -9.5%on this news
Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates Biologics License Application (BLA) for investigational microbiome therapeutic SER-109 for recurrent C. difficile infection (r
Seres Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates Biologics License Application (BLA) for investigational microbiome therapeutic SER-109 for recurrent C. difficile infection (rCDI) accepted for Priority Review by U.S. Food and Drug Ad
Read more →MCRB▲ +8.5%on this news· ran to +19% by day 1
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates Expect to complete SER-109 Biologics License Application filing in the coming weeks Reported confirmatory SER-109 Phase 3 stu
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Expect to complete SER-109 Biologics License Application filing in the coming weeks Reported confirmatory SER-109 Phase 3 study results, including in individuals with a first recurrence of C. diffici
Read more →MCRB▲ +28.8%on this news
Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, the timing and potential approval of SER-109
SER-109 ECOSPOR IV Study Results June 7, 2022 Exhibit 99.1 Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, the timing and potential approval of SER-10
Read more →MCRBSeres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates SER-109 open label study results, including safety and efficacy data, including in over 260 individuals enrolled with recurren
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates SER-109 open label study results, including safety and efficacy data, including in over 260 individuals enrolled with recurrent C. difficile infection, anticipated in Q2 2022 FDA agre
Read more →MCRBSome of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential approval of SER-109 and its sta
Corporate Overview April 2022 Exhibit Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, the potential approval of SER-109 and its status as a first-in-cl
Read more →MCRB▼ -7.6%on this news· ran to -21% by day 3
Seres Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates SER-109 Phase 3 study results in recurrent C. difficile infection published in New England Journal of Medicine
Seres Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business SER-109 Phase 3 study results in recurrent C. difficile infection published in New England Journal of Medicine Biologics License Application (BLA) filing for SER-109 anticipat
Read more →MCRB▲ +20.4%on this news
Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates Enrollment completed in SER-109 recurrent C. difficile infection open-label study Company expects both completed SER-109 Phase
Seres Therapeutics Reports Third Quarter 2021 Financial Results and Provides Enrollment completed in SER-109 recurrent C. difficile infection open-label study Company expects both completed SER-109 Phase 3 study results and pending safety database to support finalization of Bi
Read more →MCRBSeres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates SER-109 open-label study in patients with recurrent C. difficile infection on track to achieve enrollment target in late Q3 2
Seres Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Updates SER-109 open-label study in patients with recurrent C. difficile infection on track to achieve enrollment target in late Q3 2021 SER-109 co-commercialization agreement with Nestl Hea
Read more →MCRBSeres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis Primary endpoint of clinical remission compared to placebo was not achieved Both dosing regimens of SER-287 w
Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis Primary endpoint of clinical remission compared to placebo was not achieved Both dosing regimens of SER-287 were generally well tolerated Open label and maintenance
Read more →MCRBSeres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development May 20, 2021 8:00 AM Eastern Standard Time Mass. Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that David Arkowitz will join as Ex
Read more →MCRBSeres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates Topline clinical data from SER-287 Phase 2b study in patients with mild-to-moderate ulcerative colitis expected in mid-2021, m
Seres Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates Topline clinical data from SER-287 Phase 2b study in patients with mild-to-moderate ulcerative colitis expected in mid-2021, microbiome biomarker data anticipated in H2 2021 Ongoing e
Read more →MCRBSeres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates SER-287 Phase 2b study in patients with mild-to-moderate ulcerative colitis has achieved target enrollment; top
Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business SER-287 Phase 2b study in patients with mild-to-moderate ulcerative colitis has achieved target enrollment; topline data expected in mid-2021 Continued enrollment in SER-109 op
Read more →MCRBSome of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, our development plans, the promise and potent
Seres Therapeutics Eric Shaff, Chief Executive Officer 39th Annual J.P. Morgan Healthcare Conference January 14, 2021 Exhibit 99.1 Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, in
Read more →MCRBForward Looking Statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, our development pl
Seres Therapeutics Overview SER-109 ECOSPOR III top-line study results August 10, 2020 Exhibit 99.1 Forward Looking Statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, includ
Read more →MCRBSeres Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates Data from Phase 3 study of SER-109 in recurrent C. difficile infection expected mid-2020; Potential to be the single pivotal s
Seres Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates Data from Phase 3 study of SER-109 in recurrent C. difficile infection expected mid-2020; Potential to be the single pivotal study supporting product registration with the FDA Webcast
Read more →MCRBSeres Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Highlights Data-rich period ahead including two expected late-stage microbiome clinical readouts: SER-109 in recurrent C. diffi
Seres Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Highlights Data-rich period ahead including two expected late-stage microbiome clinical readouts: SER-109 in recurrent C. difficile infection in mid-2020 and SER-287 for ulcerative coli
Read more →MCRBSeres Therapeutics Reports Third Quarter Financial Results and Provides Business Update Two late-stage microbiome clinical study readouts in ulcerative colitis and C. difficile infection anticipated in 2020 Debt facility
Seres Therapeutics Reports Third Quarter Financial Results and Provides Business Update Two late-stage microbiome clinical study readouts in ulcerative colitis and C. difficile infection anticipated in 2020 Debt facility secured, providing up to $50 million in additional capi
Read more →MCRBSeres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update - Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs
Seres Therapeutics Reports Second Quarter Financial Results and Provides Progress Update - Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs - Completed public offering of common stock, raising net p
Read more →MCRBSeres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update - Four significant microbiome program milestones expected during 2020, including readouts from two late-stage deve
Seres Therapeutics Reports First Quarter Financial Results and Provides Clinical Pipeline Progress Update - Four significant microbiome program milestones expected during 2020, including readouts from two late-stage development programs - SER-287 Fast Track designation obtaine
Read more →MCRBSeres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates - Initiated SER-287 Phase 2b study in mild-to-moderate ulcerative colitis - - Initiated SER-401 Phase 1b study in
Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates - Initiated SER-287 Phase 2b study in mild-to-moderate ulcerative colitis - - Initiated SER-401 Phase 1b study in metastatic melanoma - - Conference call at 8:30 a.m. E
Read more →MCRBSeres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates - Kevin Horgan, M.D. an accomplished drug developer and immunology expert, hired as Chief Medical Officer - - Planning for two n
Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates - Kevin Horgan, M.D. an accomplished drug developer and immunology expert, hired as Chief Medical Officer - - Planning for two new microbiome clinical studies in ulcerative colitis and
Read more →MCRBSome of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, our development plans, the ability of ECOSPOR
Corporate Overview August 2018 Exhibit Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, our development plans, the ability of ECOSPOR III to support SER
Read more →MCRBSeres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates - Company preparing to initiate SER-287 Phase 2b study for ulcerative colitis - - Initiation of SER-401 clinical study expected
Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates - Company preparing to initiate SER-287 Phase 2b study for ulcerative - Initiation of SER-401 clinical study expected in patients with metastatic melanoma treated with checkpoint inhi
Read more →MCRBSeres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates Preclinical data provide mechanistic insights related to the potency of microbiome therapeutics to augment immuno-oncology treat
Seres Therapeutics Reports First Quarter Financial Results and Provides Operational Updates Preclinical data provide mechanistic insights related to the potency of microbiome therapeutics to augment immuno-oncology treatments; initiation of clinical study in metastatic melanoma
Read more →MCRBSeres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates - Positive SER-287 Phase 1b clinical and microbiome results support further development; Company plans to initi
Seres Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Updates - Positive SER-287 Phase 1b clinical and microbiome results support further development; Company plans to initiate next clinical trial in mid-2018 - - Preliminary Phas
Read more →MCRBSome of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements on the timing and results of our c
J.P. Morgan Healthcare Conference Roger J. Pomerantz, M.D. January 11, 2018 President, Chief Executive Officer and Chairman Exhibit 99.1 Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 19
Read more →MCRBSeres Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Operational Progress Positive results from SER-287 Phase 1b study in mild-to-moderate Ulcerative Colitis; Company to move program int
Seres Therapeutics Reports Third Quarter 2017 Financial Results and Provides Update on Operational Progress Positive results from SER-287 Phase 1b study in mild-to-moderate Ulcerative Colitis; Company to move program into further development Company awarded CARB-X grant to ad
Read more →MCRBForward looking statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including statements on the timing of additional
SER-287 Phase 1b Ulcerative Colitis study results review October 2017 Exhibit 99.1 Forward looking statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995, including statements on
Read more →MCRBSeres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational Progress - Initiated SER-109 Phase 3 study in patients with multiply recurrent C. difficile infection - - SER-287 Phase
Seres Therapeutics Reports Second Quarter 2017 Financial Results and Provides Update on Operational - Initiated SER-109 Phase 3 study in patients with multiply recurrent C. difficile - SER-287 Phase 1b study in mild-to-moderate ulcerative colitis patients, failing first line th
Read more →MCRBForward looking statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors, risks and
Corporate Presentation June 2017 Forward looking statements Some of the statements in this presentation constitute "forward looking statements" under the Private Securities Litigation Reform Act of 1995. Such statements are subject to factors, risks and uncertainties (such as t
Read more →MCRBSeres Therapeutics Reports First Quarter 2017 Financial Results and Provides Update on Operational Progress - Pre-enrollment activities underway for SER-109 ECOSPOR III clinical study initiation; Company expects study st
Seres Therapeutics Reports First Quarter 2017 Financial Results and Provides Update on Operational - Pre-enrollment activities underway for SER-109 ECOSPOR III clinical study initiation; Company expects study start in mid-year - - Continued pipeline progress with both SER-287
Read more →MCRBSeres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update - Positive SER-109 Type B FDA meeting - - Company to initiate new Phase 2 SER-109 clinical trial tha
Seres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update - Positive SER-109 Type B FDA meeting - - Company to initiate new Phase 2 SER-109 clinical trial that, as agreed to by the FDA, may qualify as a Pivotal Stu
Read more →MCRBSeres Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update Company highlights progress in commercial preparedness, pipeline expansion Strong financial position; existing c
Seres Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update Company highlights progress in commercial preparedness, pipeline expansion Strong financial position; existing cash expected to support operations well into 2018 CAMBRI
Read more →MCRBSeres Therapeutics Reports Third Quarter 2015 Financial Results and Provides Business Update FDA granted Orphan Drug Designation for SER-109 in recurrent C. difficile Infection (CDI) CAMBRIDGE, Mass. (BUSINESS WIRE)
Seres Therapeutics Reports Third Quarter 2015 Financial Results and Provides Business Update FDA granted Orphan Drug Designation for SER-109 in recurrent C. difficile Infection (CDI) CAMBRIDGE, Mass. (BUSINESS WIRE) Nov. 10, 2015 Seres Therapeutics (NASDAQ: MCRB), a leading mic
Read more →MCRBSeres Therapeutics, Inc. (Nasdaq: MCRB) to Ring The Nasdaq Stock Market Closing Bell
ADVISORY, Aug. 19, 2015 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq:MCRB), a leading microbiome therapeutics platform company, will visit the Nasdaq MarketSite in Times Square. In honor of the occasion, Roger Pomerantz, President and Chief Executive Officer, will ring
Read more →MCRBSeres Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update - Phase 2 study initiated for lead microbiome therapeutic SER-109 for prevention of recurrent Clostridium difficile infection
Seres Therapeutics Reports Second Quarter 2015 Financial Results and Provides Business Update - Phase 2 study initiated for lead microbiome therapeutic SER-109 for prevention of recurrent Clostridium difficile infection (CDI) in adults - FDA Breakthrough Therapy Designation re
Read more →Competitive Position
How MCRB ranks across every disease it competes inCompetitive Position is a premium feature
See how MCRB ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial